Jonathan Shillingford
Affiliations: | 2003-2012 | Department of Molecular, Cellular & Developmental Biology | University of California, Santa Barbara, Santa Barbara, CA, United States |
Google:
"Jonathan Shillingford"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Shillingford JM, Shayman JA. (2023) Functional TFEB activation characterizes multiple models of renal cystic disease and loss of polycystin-1. American Journal of Physiology. Renal Physiology |
| Weimbs T, Shillingford JM, Torres J, et al. (2018) Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease. Clinical Kidney Journal. 11: i27-i38 |
| Kipp KR, Kruger SL, Schimmel MF, et al. (2018) Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease. American Journal of Physiology. Renal Physiology |
| Shillingford JM, Leamon CP, Vlahov IR, et al. (2012) Folate-conjugated rapamycin slows progression of polycystic kidney disease. Journal of the American Society of Nephrology : Jasn. 23: 1674-81 |
| Stayner C, Shields J, Slobbe L, et al. (2012) Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus. Nephrology (Carlton, Vic.). 17: 739-47 |
| Olsan EE, Mukherjee S, Wulkersdorfer B, et al. (2011) Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease. Proceedings of the National Academy of Sciences of the United States of America. 108: 18067-72 |
| Talbot JJ, Shillingford JM, Vasanth S, et al. (2011) Polycystin-1 regulates STAT activity by a dual mechanism. Proceedings of the National Academy of Sciences of the United States of America. 108: 7985-90 |
| Shillingford JM, Piontek KB, Germino GG, et al. (2010) Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. Journal of the American Society of Nephrology : Jasn. 21: 489-97 |
| Shillingford JM, Murcia NS, Larson CH, et al. (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proceedings of the National Academy of Sciences of the United States of America. 103: 5466-71 |
| Hedgepeth RC, Goldfarb DA, Shillingford JM, et al. (2006) 549: The Effect of Rapamycin Immunosuppression on Native Polycystic Kidney Volumes in Renal Transplant Patients Journal of Urology. 175: 178-178 |